Comparative Effectiveness of Peripheral Nerve Stimulation in Neuropathic Pain: Multi-Center Cohort Study and Cost-Effectiveness Analysis
Neuropathic pain affects millions of people worldwide. It often resists standard treatments. Doctors need better options for long-term relief. Peripheral nerve stimulation (PNS) has emerged as a promising solution. Researchers conducted a multi-center cohort study to compare its effectiveness.
Study Design and Participants The team followed 285 patients across five major hospitals. All participants suffered from chronic neuropathic pain. Researchers divided them into two groups. One group received peripheral nerve stimulation. The other group continued with conventional medical management. They tracked outcomes for 18 months.
Key Effectiveness Results Patients who received PNS reported significant pain reduction. Their average pain scores dropped by 62% within six months. Moreover, they needed fewer pain medications over time. In contrast, the conventional group showed only a 28% improvement. Additionally, PNS patients experienced better sleep quality and daily functioning. As a result, their overall quality of life improved markedly.
Functional and Safety Outcomes Participants in the PNS group returned to work faster. They also walked longer distances without discomfort. Furthermore, complication rates remained low. Only 8% of patients needed minor device adjustments. Therefore, the treatment proved both effective and relatively safe.
Cost-Effectiveness Analysis Researchers calculated total healthcare costs for both groups. Initial PNS implantation costs more than standard drugs. However, savings appeared within the first year. PNS patients made fewer hospital visits and used less medication. The analysis showed an incremental cost-effectiveness ratio of $18,450 per quality-adjusted life year gained. This value falls well within accepted cost-effectiveness thresholds.
Long-Term Benefits After 18 months, 71% of PNS patients continued to experience meaningful pain relief. In comparison, only 34% of the conventional group reported sustained benefits. Moreover, PNS reduced the economic burden on patients and healthcare systems. These findings support wider use of this technology.
Conclusion Peripheral nerve stimulation delivers superior pain relief compared to conventional treatments. It improves patient function and quality of life. At the same time, it proves cost-effective over the medium term. Healthcare providers should consider PNS earlier for patients with refractory neuropathic pain. Future studies can explore its benefits in larger and more diverse populations. This approach brings new hope to people living with persistent nerve pain.